Primary biliary cholangitis is a chronic cholestatic disease characterized by autoimmune-mediated destruction of bile ducts, leading to fibrosis, cirrhosis, & liver failure. Ursodeoxycholic acid is 1st line Rx. New Rx include elafibranor & seladelpar (activates peroxisome https://t.co/tKloXvJYek

UK primary care database (2000–21) gout study of new colchicine initiators (n 31,478) vs noninitiators (mean 60 yrs, BMI 30), follow-up of 4.5 yrs. Colchicine use had a signif. 12% lower risk of Joint Arthroplasty (HR 0.88); 23% lower TJA in knee/hip OA (HR 0.77) https://t.co/bT07lUYBB2

"Gout, unlike any other disease, kills more rich men than poor, more wise men than simple." — Thomas Sydenham

NEW FROM EULAR: A real-world analysis of predictors of IBD in PsA. 🔎 In patients with PsA, signs and symptoms of IBD may appear before diagnosis, but do we know what to look for? Explore the poster: https://t.co/kvNAYH7iub Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/IMFB2jUYhN

• Real-World Predictors and Early Indicators for IBD in Patients With PsA | Rheum…

GI dz & malnutrition in scleroderma (SSc) is common, assessed by BMI. Among 450 SSc (F/U 5.3 yrs), lower BMI were significantly assoc w/ pseudoobstruction, smaller oral aperture, higher Medsger vascular severity scores. Defines those at risk https://t.co/JY9YFOWE5C https://t.co/xFZ0rCXjQv

• Determinants of body mass index in early systemic sclerosis: implications for n…

Gout and its' associated comorbidities - treat gout and its' comorbidities to target Created by : @Rheumat_aravind https://t.co/AKT3rAvDBH https://t.co/SM248IPadR

• Gout and Its Associated Comorbidities | RheumNow

RheumIQ: True or False: Severe allergic reactions to allopurinol are more common in patients with chronic kidney disease than in the general population. See if you got it right at https://t.co/LATb1P18Sh. https://t.co/dFdrhso1oU

• RheumIQ Weekly Quiz | RheumNow

Persistence of education and monitoring is crucial to optimal gout management Optimal gout care is dependent on having a well-informed health care provider who recognizes and follows the ACR gout management recommendations. It is important that the misconceptions and myths held https://t.co/XYSwvuihjJ

Patients with anemia (10% of the population) have a 2-fold increased risk of gout. For more gout content, follow our Gout: More than Flares campaign at https://t.co/lQoiFjubZJ, https://t.co/s8HeS9sbu0

• Gout Campaign - July 2026 | RheumNow

Expert Perspective on Calcium Pyrophosphate Deposition Disease A current perspective article by Dr. Sara Tedeschi tackles many unresolved issues around CPPD diagnosis, classification, and management, including the lack of clinical trials or FDA approved treatments. https://t.co/zxJ9aQweNl

Pragmatism in Gout: How therapeutic choices can have multiple benefits William James famously wrote in Pragmatism, “There can be no difference anywhere that doesn’t make a difference elsewhere.” Gout treatment offers a striking medical example of that idea. https://t.co/DG29pro6XE

Gout and its' associated comorbidities - treat gout and its' comorbidities to target https://t.co/U0dolcAGEc https://t.co/mGvYQrWx25

• Gout and Its Associated Comorbidities | RheumNow

Among 784,091 pts in a UK acute MI registry, 715 (0.1%) had SLE. SLE pts were younger & more female. SLE w/ MI had signif higher adjusted all-cause mortality from 30 days (HR 1.62) to 5 years (HR 1.84), despite age & having less traditional cardiovascular comorbidities https://t.co/78oHVWTdTJ

Nerandomilast (Jascayd) has been approved in the European Union for adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The drug was approved for IPF & PPF by the FDA for US use in late 2025 https://t.co/scOuVb3aYy https://t.co/EcmpRhyWgu

• EU approves Jascayd as first new IPF oral treatment in a decade

Coding: ICD-10 Code M45.7 describes ankylosing spondylitis of the lumbosacral region, a billable ICD-10-CM diagnosis code valid for FY2026. M45.7 became effective October 1, 2025 and belongs to the M45 parent category covering ankylosing spondylitis by anatomical site. https://t.co/jBmoD0CVps